Introduction: The Next Step of CAR-T Is Not “Better” — It’s “Simpler” Over the past decade, CAR-T therapy has proven that we can treat cancer with engineered immune cells. But the real bottleneck is never efficiency, but rather: Too high cost The manufacturing process is too slow Patients can't wait The essence of traditional CAR-T is actually "personalized cell manufacturing". Now, a more fundamental question has arisen: What if CAR-T didn't need to be manufactured at all? T

In Vivo CAR-T Autoimmune Therapy: Reprogramming the Immune System In Situ Introduction CAR-T therapy has already transformed hematologic oncology. Yet its expansion into autoimmune disease has been limited by cost, manufacturing complexity, and scalability challenges. A new paradigm is emerging: in vivo CAR-T autoimmune therapy . Instead of extracting T cells, engineering them ex vivo, and reinfusing them weeks later, in vivo approaches program immune cells directly inside th